BioMarin Pharmaceutical Inc. BMRN
Composite 42/100; the shares have moved about 34% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Momentum ranks 53/100 — a slight point in its favour. Growth ranks 50/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Quality ranks 38/100 — a moderate mark against it. Balance-sheet strength ranks 49/100 — a slight mark against it.
What the company does BioMarin Pharmaceutical develops and commercializes enzyme replacement and other therapies for rare, life-threatening diseases such as MPS IVA (VIMIZIM), achondroplasia (VOXZOGO), and Batten disease (BRINEURA).
Key financials Revenue grew 2.8% YoY while EPS fell 43.1%. Margins are 51.2% gross, 18.0% operating, and 8.3% net. ROE is 4.5%, ROA 4.5%, and ROCE 5.2%. Debt/Equity is 0.23 with net cash and a current ratio of 5.81.
Stock health Sidera’s overall score is 50.3 (Weak quality, fairly valued). Strength is high at 93.1, but quality (37.2) and growth (25.5) lag. RSI(14) is 51.90 and 3-month momentum is 10.15%.
Price vs fair value BioMarin trades at a discount of 25.40% to our fair-value estimate of 74.46 and a discount of 48.06% to the 12-month target of 87.92. - Analysts expect a decline in BMRN’s earnings (Zacks 2026-07-27) - Partnership with n-Lorem signals early-stage pipeline progress (Pharmaceutical Technology 2026-07-28) - Peer earnings beats (ACAD) may be pressuring biotech sentiment (Zacks 2026-07-28)
Looking forward Forward P/E of 11.96 and PEG of 0.05 imply undemanding multiples, but weak growth and quality scores temper enthusiasm. Pipeline catalysts (e.g., ReNU syndrome) could re-rate the stock if clinical progress is demonstrated.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.